BIOMAT Database Logo BIOMAT Database Logo

[Therapy of polycythemia vera with myleran]. 1965

E Krykowski, and B Wislawska, and E Polkowska-Kulesza

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011087 Polycythemia Vera A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs. Erythremia,Osler-Vaquez Disease,Polycythemia Rubra Vera,Polycythemia Ruba Vera,Primary Polycythemia,Disease, Osler-Vaquez,Erythremias,Osler Vaquez Disease,Polycythemia Ruba Veras,Polycythemia Rubra Veras,Polycythemia, Primary,Polycythemias, Primary,Primary Polycythemias,Ruba Vera, Polycythemia,Ruba Veras, Polycythemia,Vera, Polycythemia Ruba,Vera, Polycythemia Rubra,Veras, Polycythemia Ruba,Veras, Polycythemia Rubra
D002066 Busulfan An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen. Busulphan,Busulfan Wellcome,Busulfex,Glyzophrol,Myelosan,Mylecytan,Myleran,Myléran,n-Butane-1,3-di(methylsulfonate),Wellcome, Busulfan
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

E Krykowski, and B Wislawska, and E Polkowska-Kulesza
Therapy of polycythemia vera with myleran.
August 1958, Blood,
E Krykowski, and B Wislawska, and E Polkowska-Kulesza
Treatment of polycythemia vera with myleran.
February 1961, The American journal of the medical sciences,
E Krykowski, and B Wislawska, and E Polkowska-Kulesza
[Results of busulfan (myleran) therapy of polycythemia vera].
April 1969, Polskie Archiwum Medycyny Wewnetrznej,
E Krykowski, and B Wislawska, and E Polkowska-Kulesza
[Myleran treatment in polycythemia vera].
August 1971, Nordisk medicin,
E Krykowski, and B Wislawska, and E Polkowska-Kulesza
Treatment of polycythemia vera with busulfan (myleran).
December 1958, Journal of the American Medical Association,
E Krykowski, and B Wislawska, and E Polkowska-Kulesza
[A case of polycythemia vera treated with myleran].
May 1966, Wiadomosci lekarskie (Warsaw, Poland : 1960),
E Krykowski, and B Wislawska, and E Polkowska-Kulesza
[Case of polycythemia vera remitting with administration of Myleran].
October 1969, Naika. Internal medicine,
E Krykowski, and B Wislawska, and E Polkowska-Kulesza
[Fatal pancytopenia after treatment of polycythemia vera with myleran].
September 1960, Schweizerische medizinische Wochenschrift,
E Krykowski, and B Wislawska, and E Polkowska-Kulesza
[Therapy of polycythemia vera with busulfan (myleran). Report on results in 40 patients].
January 1970, Folia haematologica (Leipzig, Germany : 1928),
E Krykowski, and B Wislawska, and E Polkowska-Kulesza
The treatment of Polycythemia vera and thrombocythemia with myleran (busulphan).
July 1965, Israel journal of medical sciences,
Copied contents to your clipboard!